Top Story

Morning Read: JP Morgan 2016 (the final chapter)

Last call for #jpm16. Also, iHealthBeat is shutting down, what's next for BioMarin and meet the new Centers for Common Disease Genomics.

Jamie Dimon JP Morgan healthcare

TOP STORIES

JP Morgan’s 2016 healthcare conference – and the Health-apalooza around it – have wound down. See all of MedCity News’ coverage here (there’s still more to come). But here’s some of the notable coverage from Thursday:

  • Celgene CEO: Any company that expects to have a major position in the industry a decade from now will almost have to play a big role in developing therapies for neurodegeneration. – FierceBiotech
  • Optimism After A Stormy Week For The Biotech Markets – Life Sci VC
  • At night JP Morgan “is the closest biotech gets to a stay in Vegas, with plenty of booze and entertainment.” – FierceBiotech
  • Sector Searches For Ways To Turn Pricing Debate – SeekingAlpha
  • Top 10 trends from the JP Morgan Healthcare Conference – Becker’s Hospital Review
  • Balding heads. Buzzwords. Biotech execs refine the art of the pitch. – STAT
  • Health-care companies had their strongest advance in more than four months to recover from their biggest slide since Sept. 29. – Bloomberg
  • A biotech venture capitalist explains his 3 criteria for new investments – Business Insider
  • Conference sessions surfaced interesting questions and approaches regarding the post-acute sector, bundled payment, emergency medicine and anesthesia. – Healthcare Law Blog

LIFE SCIENCES

No word yet on what’s next for BioMarin Pharmaceuticals after the FDA rejected its Duchenne muscular dystrophy treatment. This is not much of a surprise considering a November review of the drug. The FDA has asked for another trial (BioMarin will meet with the agency soon). – Bloomberg

A nice breakdown of the patent dispute around CRISPR between the Broad Institute and UC Berkeley. – KQED

Canadian medical device company Conavi won an FDA 510(k) clearance for its Foresight ICE System ultrasound device for cardiac and great vessel anatomy. – MassDevice

The Broad Institute, Washington University in St. Louis; Baylor College of Medicine and the New York Genome Center will combine to form the Centers for Common Disease Genomics, fueled by $260 million in federal money. – STAT

Deciphera Pharmaceuticals added $15 million from SV Life Sciences on top of its recent $75 million fund-raise. – Kansas City Business Journal

Keep an eye on this: “France Clinical Trial Goes Awry, Leaving One Volunteer Brain Dead and 5 Others Hospitalized.” – NBC

PAYERS-PROVIDERS

Woah. iHealthBeat is shutting down. Here’s a note subscribers got:

We are writing to let you know that, as of February 1, the California Health Care Foundation will no longer publish iHealthBeat (iHB), our health information technology (HIT) news service.

While iHB has been a valuable resource, its exclusive focus on HIT no longer aligns with the programmatic focus of our work at the California Health Care Foundation. Thank you for being a subscriber to iHealthBeat.
The California HealthCare Foundation

Here’s a feel-good healthcare story: Shlomo Rechnitz, a health care magnate who owns 80 assisted living facilities throughout California, purchased nearly 18,000 lottery tickets for all of his employees. – Jerusalem Post

TECHNOLOGY

Read all eight digital health trends in 2016. But I like this one the best: “The hype around consumer wearables will cool, but condition-specific and enterprise health wearables will thrive.” – CB Insights

Healthcare IT funding in 2015 dropped by about $100 million from the previous year, down to $4.6 billion, according to Mercom Capital Group. – MobiHealthNews

Call9, which offers emergency care via video visits to nursing homes, raised $10 million in a round led by Index Ventures. – MobiHealthNews

POLITICS

Two takes on the cancer moonshot: 7 ways to tell if it’s real and one point of view it has absolutely no shot. – STAT, Pharyngula

Ugh. “F.D.A.’s data on post-market safety issues and studies were found to be incomplete, outdated, to contain inaccuracies, and to be stored in a manner that made routine, systematic analysis difficult.” – The New York Times

Here’s an update from the FDA about its efforts to improve clinical trial design: from quality and comprehensiveness of demographic subgroup data collection, reporting and analysis to to improving transparency of subgroup data. Its public meeting on the topic is scheduled for Feb. 29.  – FDA Voice

Democratic stalwart Howard Dean now lobbies on behalf of healthcare and against Bernie Sanders. This makes some people sad. – The Intercept

A LITTLE BIT EXTRA

Yes, the president wants to spend $4 billion on automated vehicles – aka. self-driving cars. Here’s what’s fact and fiction. – Gizmodo

Photo: Getty Images

Shares0
Shares0